BPG is committed to discovery and dissemination of knowledge
Featured Articles
9/7/2026 6:12:35 AM | Browse: 8 | Download: 0
 |
Received |
|
2026-02-24 01:05 |
|
Peer-Review Started |
|
2026-02-24 01:05 |
|
First Decision by Editorial Office Director |
|
2026-04-10 09:33 |
|
Return for Revision |
|
2026-04-10 09:33 |
|
Revised |
|
2026-04-16 08:01 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2026-05-22 02:38 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2026-05-22 06:22 |
|
Articles in Press |
|
2026-05-22 06:22 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2026-07-09 09:41 |
|
Publish the Manuscript Online |
|
2026-09-07 02:26 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
Open-Access: This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Copyright |
©Author(s) (or their employer(s)) 2026. No commercial re-use. See Permissions. Published by Baishideng Publishing Group Inc. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Editorial |
| Article Title |
Thalidomide for refractory hemorrhagic chronic radiation proctitis: Bridging the gap between symptom control and disease-modifying therapy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ya Deng, Zhi-Min Du, Hong-Fang Li and Fu-Shan Tang |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Fu-Shan Tang, PhD, Professor, Department of Clinical Pharmacy, Key Laboratory of Basic Pharmacology of Guizhou Province and School of Pharmacy, Zunyi Medical University, No. 6 Xuefu West Road, Xinpu New District, Zunyi 563006, Guizhou Province, China. fstang@vip.163.com |
| Key Words |
Chronic radiation proctitis; Thalidomide; Pathogenesis; Drug therapy; Survivorship care |
| Core Tip |
Low-dose thalidomide demonstrated an 83.9% clinical remission rate and favorable safety profile in refractory hemorrhagic chronic radiation proctitis (CRP) during a phase II trial, suggesting its potential as a systemic therapeutic option based on preliminary evidence. The observed discrepancy between symptom improvement and endoscopic findings underscores the necessity of including patient-reported outcomes alongside traditional objective metrics. This article reviews the pathogenesis and treatment options for CRP, interprets thalidomide’s clinical significance, evaluates the limitations of the study, and advocates for mechanism-based comprehensive management strategies during cancer survivorship. |
| Publish Date |
2026-09-07 02:26 |
| Citation |
Deng Y, Du ZM, Li HF, Tang FS. Thalidomide for refractory hemorrhagic chronic radiation proctitis: Bridging the gap between symptom control and disease-modifying therapy. World J Gastroenterol 2026; 32(38): 120289
|
| URL |
https://www.wjgnet.com/1007-9327/full/v32/i38/120289.htm |
| DOI |
https://doi.org/10.3748/wjg.120289 |
Copyright © 1993-2026 Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA. All rights reserved, including rights relating to text and data mining, AI training, and similar technologies. For open-access content, the applicable copyright and licensing terms govern.
